Development of Diagnostic and Treatment Tactics for Non-Muscle-Invasive Bladder Cancer Using Minimally Invasive Technologies

Yusupbekov A. A; Tillyashaikhova R. M; Tuychiev A. P.

Authors

Yusupbekov A. A Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan
Tillyashaikhova R. M Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan
Tuychiev A. P. Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan

Vol. 2 No. 11 (2024): International Journal of Integrative and Modern Medicine

Articles

November 18, 2024

Non-muscle invasive bladder cancer accounts for 75% of the total number of patients with bladder cancer, but is characterized by a pronounced tendency to relapse in 50-70%, with 10-30% of them progressing to invasive and metastatic forms. Problems, early diagnosis and new methods of treating non-invasive cancer are discussed. stage 1 bladder cancer.

A. A, Y., R. M, T., & A. P., T. (2024). Development of Diagnostic and Treatment Tactics for Non-Muscle-Invasive Bladder Cancer Using Minimally Invasive Technologies. International Journal of Integrative and Modern Medicine, 2(11), 211–220. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/1174

Download Citation

Tillyashaykhov M.N., Ibragimova Sh.N., Dzhanklich S.M. The state of oncological care for the population of the Republic of Uzbekistan in 2019 // Fundamental research - 2020.-№1.- P.8.

Matveyev B.P., Figurin K.M., Karyakin O.B. Bladder cancer // Oncourology .- 2017.-12.-P54.

Malignant neoplasms in Russia and 2010 (incidence and mortality). Ed. V.I. Chissov, V.V. Starinsky, G.V. Petrova. M., 2020.

Matveyev B.P. Clinical oncourology. M., 2021.

Dominguez G., Carballido J., Silva J. et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. ClinCancerRes2020;8:980-5.

Rusakov I.G., Bystrov A.A. Surgical treatment, chemo- and immunotherapy of patients with superficial bladder cancer. Practoncol2023;1:107-16.

Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol1999;162:74-6.

Klan. R., Loy V., Huland H. Residual tumor discovered in routine second TUR in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 2022;146:316.

Herr H., Dalbagni G. Is second-look (re-staging) Transurethral resection of bladder tumors a new standard of care? Arab J Urol2021;9:7-10.

Ali M.H., Ismail I.Y., Eltobgy A., Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer. J Endourol 2020;24(12):2047-50.

Dalbagni G., Vora K., Kaag M. et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1. Blad Cancer 2023;56:903-10.

Divrik R.T., Ali F.S., et al. Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective randomized Clinical Trial. Eur Urol 2020;5(8):185-90.

Han K.S., Kyung Seok Han, Jae Young Joung et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer. J Endourol2008;22(12):2699-704.

Schips L., Augustin H., Zigeuner R.E. et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2022;59(2):220-3.

Schwaibold H.E., Sivalingam S., May F. et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:1199-201.

Cheng L., Montironi R., Davidson D., Lopez-Beltran A. Staging and reporting of urothelialcarcinomaof the urinary bladder. Mod Pathol2023;22:70-95.

Zlotta A.R., van Vooren J.P., Huygen K. et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2023;37(4):470-7. 18. Herr H.W. restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol2020;174:2134-7.

Stern M. Resections of obstructions at the vesical orifice. J Am Med Asso 2019;87:1726-9.

Herr H.W., Donat S.M., Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? Department of Urology, Memorial Sloan-Kettering Cancer Center. New York. NY, 2017.

Grimm M.O., Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2023;170(2 Pt 1):433-7.

Kulkarni G.S., Oliver W. Hakenberg, Juergen E. Gschwend et al. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previosly T1G3) Bladder Cancer Accepted 26 August 2020. Eur Urol 2020;57(1):60-70.

International Journal of Integrative and Modern Medicine

Development of Diagnostic and Treatment Tactics for Non-Muscle-Invasive Bladder Cancer Using Minimally Invasive Technologies

Authors

Downloads

Similar Articles

submenu

counter